Cytokinetics, Inc. (NASDAQ:CYTK) reported total research and development revenues for the second quarter of 2015 were $6.
In today’s market with most biotech companies sporting bloated valuations it can be hard for investors to find stocks with significant upside. I …
In a research report released on Wednesday, Cowen analyst Ritu Baral initiated coverage on shares of Cytokinetics Inc. (NASDAQ:CYTK) with an Outperform rating and …
Cytokinetics, Inc. (NASDAQ:CYTK) and The ALS Association announced that The Association has awarded Cytokinetics a $1.
I’ve written about Cytokinetics, Inc. (NASDAQ:CYTK), a biopharmaceutical company that is the industry leader in developing drugs that modulate muscle function, a …
In a research report sent to investors today, MLV analyst George Zavoico reiterated a Buy rating on Cytokinetics, Inc. (NASDAQ:CYTK) with a $9.
